CoronaVac shows moderate efficacy in Phase III studies

8 February 2021
china_credit_depositphotos_large

China’s Sinovac has reported positive Phase III data for its coronavirus vaccine, CoronaVac, with 50.65% overall efficacy after two weeks, following two doses.

Based on clinical trials taking place in Brazil and Turkey, results show the vaccine was 83.7% effective at preventing severe cases and 100% effective against hospitalization or death.

On Saturday, the Chinese regulator granted Sinovac emergency approval for the product, making it the second vaccine OK’d for general use in the country.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology